About the Authors
- Reinhard Hinterleitner
-
Contributed equally to this work with: Reinhard Hinterleitner, Thomas Gruber, Christa Pfeifhofer-Obermair, Christina Lutz-Nicoladoni, Dominik Wolf, Gottfried Baier
Affiliation Department of Pharmacology and Genetics, Medical University Innsbruck, Innsbruck, Austria
- Thomas Gruber
-
Contributed equally to this work with: Reinhard Hinterleitner, Thomas Gruber, Christa Pfeifhofer-Obermair, Christina Lutz-Nicoladoni, Dominik Wolf, Gottfried Baier
Affiliation Department of Pharmacology and Genetics, Medical University Innsbruck, Innsbruck, Austria
- Christa Pfeifhofer-Obermair
-
Contributed equally to this work with: Reinhard Hinterleitner, Thomas Gruber, Christa Pfeifhofer-Obermair, Christina Lutz-Nicoladoni, Dominik Wolf, Gottfried Baier
Affiliation Department of Pharmacology and Genetics, Medical University Innsbruck, Innsbruck, Austria
- Christina Lutz-Nicoladoni
-
Contributed equally to this work with: Reinhard Hinterleitner, Thomas Gruber, Christa Pfeifhofer-Obermair, Christina Lutz-Nicoladoni, Dominik Wolf, Gottfried Baier
Affiliations Department of Pharmacology and Genetics, Medical University Innsbruck, Innsbruck, Austria, Laboratory of Tumor Immunology, Tyrolean Cancer Research Institute, Innsbruck, Austria
- Alexander Tzankov
-
Affiliation Institute of Pathology, University Hospital Basel, Basel, Switzerland
- Manfred Schuster
-
Affiliation Apeiron-Biologics AG, Vienna, Austria
- Josef M. Penninger
-
Affiliation Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
- Hans Loibner
-
Affiliation Apeiron-Biologics AG, Vienna, Austria
- Günther Lametschwandtner
-
Affiliation Apeiron-Biologics AG, Vienna, Austria
- Dominik Wolf
-
Contributed equally to this work with: Reinhard Hinterleitner, Thomas Gruber, Christa Pfeifhofer-Obermair, Christina Lutz-Nicoladoni, Dominik Wolf, Gottfried Baier
Affiliations Laboratory of Tumor Immunology, Tyrolean Cancer Research Institute, Innsbruck, Austria, Department of Hematology and Oncology, Medical University Bonn, Bonn, Germany
- Gottfried Baier
-
Contributed equally to this work with: Reinhard Hinterleitner, Thomas Gruber, Christa Pfeifhofer-Obermair, Christina Lutz-Nicoladoni, Dominik Wolf, Gottfried Baier
* E-mail: Gottfried.Baier@i-med.ac.at
Affiliation Department of Pharmacology and Genetics, Medical University Innsbruck, Innsbruck, Austria
Competing Interests
Conflicts of interest: The authors hold shares in Apeiron Biologics, a company involved in the development of Cbl-b antagonists. Apeiron Biologics Forschungs and Tiroler Landeskrankenanstalten GmbH are the company partners within the COMET Center ONCOTYROL funded by the Austrian Federal Ministries BMVIT/BMWFJ (via FFG) and the Tiroler Zukunftsstiftung/Standortagentur Tirol (SAT). There has not been direct funding by these two company partners. Nevertheless and because of this fruitful cooperation, there are coauthors employed by a commercial company Apeiron-Biologics AG. Yet, this does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. The authors' names that hold shares in Apeiron Biologics are Manfred Schuster, Josef M. Penninger, Hans Loibner and Günther Lametschwandtner.
Author Contributions
Conceived and designed the experiments: RH TG CPO CLN AT MS JMP HL GL DW GB. Performed the experiments: RH TG CPO CLN AT. Analyzed the data: RH TG CPO CLN DW GB. Contributed reagents/materials/analysis tools: JMP GL. Wrote the paper: RH TG CPO GB.